Pierleone Lucatelli et al. CVIR(2019)
Featured product: Occlusafe® Temporary Occlusion Balloon Catheter
The combination of DEM-TACE with the b-TACE may improve the oncological response in HCC and the choice of a different delivery system will provide the Interventional Oncologist with another opportunity to further address the specific needs of every single patient, in line with the modern concept of individualized medicine.
To report technical success, safety profile and oncological results of balloon-occluded transcatheter arterial chemoembolization using a balloon micro-catheter and epirubicin-loaded polyethylene-glycol (PEG) microsphere in HCC
Pierleone Lucatelli et al registry demonstrated:
Pre-planned feeder was reached in all cases.
Pressure drop average was 51.1 ± 21.6 mmHg.
Exclusive target embolization was achieved in 14/24 procedures (58.3%).
Laboratory test modifications were all grade 1.
4/24 adverse events occurred (17%): pseudo-aneurysm of the feeder (grade 3), liver abscess (grade 2) and 2 asymptomatic segmentary biliary tree dilatations (grade 2).
Post-embolisation syndrome PES occurred in 8/24 (33%).
The complete response at 1 and 3–6 months was 44.8% (13/29) and 52.9% (9/17)
Due to the lack of data on the b-TACE performed with DEM, the comparison with the existing literature is influenced by several causes of bias: use of lipiodol, different drugs and population characteristics (e.g. number and dimension of treated tumours).
The small sample size sample size (22 patients) and the nonrandomized nature of this series.
Pierleone Lucatelli et al concluded that Epirubicin-loaded PEG microsphere b-TACE is technically feasible, safe and effective procedure for HCC treatment.
The main findings of Pierleone Lucatelli et al are that:
Epirubicin-loaded PEG microsphere b-TACE is technically feasible, safe and effective procedure for HCC treatment.
The combination of b-TACE and DEM was safe and obtained Satisfactory complete response rates CR, at 1 and 3–6 months,
Despite the initial complexity added to the procedure by the presence of the balloon micro-catheter and the different catheter manipulation technique, the operators were able to position and inflate the balloon micro-catheter in the selected vascular segment in all cases.
Access to full publication: https://doi.org/10.1007/s00270-019-02192-y
This literature summary is not a systemic review. It is only an example of Occlusafe™ Temporary Occlusion Balloon Catheter related literatures.
©2021 TERUMO CLINICAL SUPPLY CO., LTD. CE0344Manufacturer
TERUMO CLINICAL SUPPLY CO., LTD.
Kakamigahara Gifu, Japan 501-6024
Terumo Europe N.V.
3001 Leuven Belgium
Tel: +32 16 38 12 11
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.